Track BridgeBio Oncology Therapeutics's long-term debt ($1.8M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (September 2026), BBOT shows a long-term debt of $1.8M. That compares with $2.4M in the prior-year period — down 24.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, BBOT's long-term debt is now $1.8M (was $2.4M) — a 24.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether BridgeBio Oncology Therapeutics is outperforming or lagging.
Tracking BBOT's long-term debt over time shows whether BridgeBio Oncology Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $1.8M That compares with $2.4M in the prior-year period — down 24.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has BridgeBio Oncology Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $1.8M) with ownership activity and broader fundamentals.